Lupin receives USFDA nod for Lorazepam Oral Concentrate
Feb 21 2013 , New Delhi
Lupin Pharmaceuticals Inc, a subsidiary of Lupin, has received final approval from US Food and Drug Administration (USFDA) for its Lorazepam Oral Concentrate USP, Lupin Ltd said in a statement.
The Mumbai-headquartered firm's product is a generic version of Roxane Inc's Lorazepam Intensol and is indicated for the management of anxiety disorders or for the short- term relief of the symptoms of anxiety or anxiety associated with depressive symptoms, it added.
According to IMS MAT September 2012 sales data, Lorazepam Oral Concentrate had annual US sales of nearly $10.7 million.
Lupin scrip closed at Rs 594 on the BSE, down 0.21 per cent from its previous close.